1 – 7 of 7
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2013
-
Mark
40K glycoPEGylated, recombinant FVIIa: 3-month, double-blind, randomized trial of safety, pharmacokinetics, and preliminary efficacy in hemophilia patients with inhibitors.
(
- Contribution to journal › Article
- 2012
-
Mark
Haemophilia Care in Europe: the ESCHQoL study
(
- Contribution to journal › Article
- 2011
-
Mark
Safety and pharmacokinetics of subcutaneously administered recombinant activated factor VII (rFVIIa).
(
- Contribution to journal › Article
- 2007
-
Mark
The economics of haemophilia prophylaxis; governmental and insurer perspectives. Proceedings of the Second International Prophylaxis Study Group (IPSG) symposium.
(
- Contribution to journal › Article
- 2003
-
Mark
Consensus perspectives on prophylactic therapy for haemophilia: summary statement.
(
- Contribution to journal › Letter
- 2002
-
Mark
Quality-of-life differences between prophylactic and on-demand factor replacement therapy in European haemophilia patients
(
- Contribution to journal › Article
-
Mark
Clinical outcomes and resource utilization associated with haemophilia care in Europe
(
- Contribution to journal › Article